FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909533581> ?p ?o ?g. }

• W2909533581 endingPage "711" @default.
• W2909533581 startingPage "707" @default.
• W2909533581 abstract "Preclinical data indicate that radiotherapy works synergistically with pembrolizumab, but the effect and toxicity of this combination may depend on radiotherapy timing. We conducted a randomized phase 1 trial combining pembrolizumab with either sequential (A) or concomitant (B) stereotactic body radiotherapy (SBRT) in metastatic urothelial carcinoma (mUC). No dose-limiting toxicity occurred. Treatment-related adverse events (trAEs; Common Terminology Criteria for Adverse Events v4.0) of grade 1–2 occurred in six of nine and all nine patients in arms A and B, respectively. One grade 3 trAE occurred in arm B. No grade 4–5 trAEs occurred. Overall response rates of 0% and 44.4% were noted in arms A and B, respectively, as per Response Evaluation Criteria in Solid Tumors v1.1. The trial was not powered to compare efficacy between arms. Targeted sequencing of tissue DNA and circulating tumor DNA (ctDNA) revealed high genomic concordance. Treatment response was associated with ctDNA fraction decline. We conclude that sequential and concomitant SBRT can be safely combined with pembrolizumab in mUC and that the effect of SBRT timing on efficacy is worth exploring further. This study assessed the safety of pembrolizumab combined with radiotherapy at two different time points in metastatic bladder cancer. We conclude that the combination treatment was well tolerated." @default.
• W2909533581 created "2019-01-25" @default.
• W2909533581 creator A5003184147 @default.
• W2909533581 creator A5019805108 @default.
• W2909533581 creator A5034237316 @default.
• W2909533581 creator A5039609539 @default.
• W2909533581 creator A5043348199 @default.
• W2909533581 creator A5044585372 @default.
• W2909533581 creator A5049733980 @default.
• W2909533581 creator A5053995382 @default.
• W2909533581 creator A5055056736 @default.
• W2909533581 creator A5055207707 @default.
• W2909533581 creator A5057365802 @default.
• W2909533581 creator A5059943416 @default.
• W2909533581 creator A5066893629 @default.
• W2909533581 creator A5073677397 @default.
• W2909533581 creator A5082271461 @default.
• W2909533581 creator A5083566572 @default.
• W2909533581 creator A5091573435 @default.
• W2909533581 date "2019-05-01" @default.
• W2909533581 modified "2023-10-08" @default.
• W2909533581 title "Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma" @default.
• W2909533581 cites W2159094759 @default.
• W2909533581 cites W2512217706 @default.
• W2909533581 cites W2559382297 @default.
• W2909533581 cites W2588916311 @default.
• W2909533581 cites W2760661635 @default.
• W2909533581 cites W2787553571 @default.
• W2909533581 cites W2888546921 @default.
• W2909533581 cites W2890683593 @default.
• W2909533581 doi "https://doi.org/10.1016/j.eururo.2019.01.009" @default.
• W2909533581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30665814" @default.
• W2909533581 hasPublicationYear "2019" @default.
• W2909533581 type Work @default.
• W2909533581 sameAs 2909533581 @default.
• W2909533581 citedByCount "75" @default.
• W2909533581 countsByYear W29095335812019 @default.
• W2909533581 countsByYear W29095335812020 @default.
• W2909533581 countsByYear W29095335812021 @default.
• W2909533581 countsByYear W29095335812022 @default.
• W2909533581 countsByYear W29095335812023 @default.
• W2909533581 crossrefType "journal-article" @default.
• W2909533581 hasAuthorship W2909533581A5003184147 @default.
• W2909533581 hasAuthorship W2909533581A5019805108 @default.
• W2909533581 hasAuthorship W2909533581A5034237316 @default.
• W2909533581 hasAuthorship W2909533581A5039609539 @default.
• W2909533581 hasAuthorship W2909533581A5043348199 @default.
• W2909533581 hasAuthorship W2909533581A5044585372 @default.
• W2909533581 hasAuthorship W2909533581A5049733980 @default.
• W2909533581 hasAuthorship W2909533581A5053995382 @default.
• W2909533581 hasAuthorship W2909533581A5055056736 @default.
• W2909533581 hasAuthorship W2909533581A5055207707 @default.
• W2909533581 hasAuthorship W2909533581A5057365802 @default.
• W2909533581 hasAuthorship W2909533581A5059943416 @default.
• W2909533581 hasAuthorship W2909533581A5066893629 @default.
• W2909533581 hasAuthorship W2909533581A5073677397 @default.
• W2909533581 hasAuthorship W2909533581A5082271461 @default.
• W2909533581 hasAuthorship W2909533581A5083566572 @default.
• W2909533581 hasAuthorship W2909533581A5091573435 @default.
• W2909533581 hasConcept C121608353 @default.
• W2909533581 hasConcept C126322002 @default.
• W2909533581 hasConcept C126894567 @default.
• W2909533581 hasConcept C143998085 @default.
• W2909533581 hasConcept C197934379 @default.
• W2909533581 hasConcept C2777701055 @default.
• W2909533581 hasConcept C2777793932 @default.
• W2909533581 hasConcept C2778375690 @default.
• W2909533581 hasConcept C2779384505 @default.
• W2909533581 hasConcept C2780057760 @default.
• W2909533581 hasConcept C509974204 @default.
• W2909533581 hasConcept C71924100 @default.
• W2909533581 hasConceptScore W2909533581C121608353 @default.
• W2909533581 hasConceptScore W2909533581C126322002 @default.
• W2909533581 hasConceptScore W2909533581C126894567 @default.
• W2909533581 hasConceptScore W2909533581C143998085 @default.
• W2909533581 hasConceptScore W2909533581C197934379 @default.
• W2909533581 hasConceptScore W2909533581C2777701055 @default.
• W2909533581 hasConceptScore W2909533581C2777793932 @default.
• W2909533581 hasConceptScore W2909533581C2778375690 @default.
• W2909533581 hasConceptScore W2909533581C2779384505 @default.
• W2909533581 hasConceptScore W2909533581C2780057760 @default.
• W2909533581 hasConceptScore W2909533581C509974204 @default.
• W2909533581 hasConceptScore W2909533581C71924100 @default.
• W2909533581 hasIssue "5" @default.
• W2909533581 hasLocation W29095335811 @default.
• W2909533581 hasLocation W29095335812 @default.
• W2909533581 hasOpenAccess W2909533581 @default.
• W2909533581 hasPrimaryLocation W29095335811 @default.
• W2909533581 hasRelatedWork W2087016115 @default.
• W2909533581 hasRelatedWork W2349164817 @default.
• W2909533581 hasRelatedWork W2569416438 @default.
• W2909533581 hasRelatedWork W2898543788 @default.
• W2909533581 hasRelatedWork W3007985759 @default.
• W2909533581 hasRelatedWork W3011133548 @default.
• W2909533581 hasRelatedWork W4281261911 @default.
• W2909533581 hasRelatedWork W4281949835 @default.
• W2909533581 hasRelatedWork W4311023586 @default.
• W2909533581 hasRelatedWork W4383619592 @default.

• next